You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

KRAS Mutated

Showing 1 - 25 of 1,045
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Solid Tumor, KRAS Mutation-Related Tumors Trial in Washington (NEROFE, Doxorubicin)

Recruiting
  • Solid Tumor
  • KRAS Mutation-Related Tumors
  • Washington, District of Columbia
    Georgetown Lombardi Comprehensive Cancer Center
Jan 23, 2023

Cholangiocarcinoma Trial (GNS561 + Trametinib)

Not yet recruiting
  • Cholangiocarcinoma
  • GNS561 + Trametinib
  • (no location specified)
May 22, 2023

Gastrointestinal Cancer Trial in New York, Providence (Cobimetinib, Hydroxychloroquine, Atezolizumab)

Active, not recruiting
  • Gastrointestinal Cancer
  • New York, New York
  • +1 more
Nov 29, 2022

NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors Trial in Belgium, Netherlands, United Kingdom (LNP3794)

Active, not recruiting
  • NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors
  • Brussels, Belgium
  • +3 more
Dec 24, 2021

Minimal Residual Disease, KRAS G12D, KRAS G12R Trial in United States (ELI-002 2P)

Recruiting
  • Minimal Residual Disease
  • +11 more
  • ELI-002 2P
  • Duarte, California
  • +10 more
Jan 18, 2023

Advanced Solid Tumor, NSCLCs Trial in Houston (Adagrasib, Olaparib)

Not yet recruiting
  • Advanced Solid Tumor
  • Non-small Cell Lung Cancers
  • Houston, Texas
    M D Anderson Cancer Center
Nov 15, 2023

KRAS P.G12C, Pancreatic Cancer Trial in Beijing (JAB-21822)

Not yet recruiting
  • KRAS P.G12C
  • Pancreatic Cancer
  • Beijing, Beijing, China
  • +1 more
Aug 18, 2023

NSCLC Trial in Baltimore (Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides
  • Baltimore, Maryland
    Johns Hopkins University
Jun 16, 2022

Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, NSCLC Trial (ELI-002 7P)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • +14 more
  • ELI-002 7P
  • (no location specified)
Feb 3, 2023

KRAS Gene Mutation, Metastatic Malignant Tumor in the Brain, Recurrent Non-Small Cell Lung Carcinoma Trial in Palo Alto

Active, not recruiting
  • KRAS Gene Mutation
  • +3 more
  • Palo Alto, California
    Stanford University School of Medicine
Feb 9, 2022

KRAS P.G12C, Non Small Cell Lung Cancer Trial in France (Sotorasib 120Mg Tab)

Recruiting
  • KRAS P.G12C
  • Non Small Cell Lung Cancer
  • Sotorasib 120Mg Tab
  • Lyon, France
  • +3 more
Dec 16, 2022

RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC

Recruiting
  • Nsclc
  • KRAS P.G12C
    • Paris, France
    • +2 more
    Aug 9, 2022

    Pancreatic Ductal Adenocarcinoma Trial in New York (VSV-GP154, ATP150, ATP152)

    Recruiting
    • Pancreatic Ductal Adenocarcinoma
    • New York, New York
      NYU Langone Health
    May 4, 2023

    Non Small Cell Lung Cancer Trial in Shanghai (Trametinib, Anlotinib)

    Recruiting
    • Non Small Cell Lung Cancer
    • Shanghai, Shanghai, China
      Shanghai Chest Hospital
    Jan 16, 2022

    Pancreatic Cancer Trial in Guangzhou (TCR-T therapy)

    Recruiting
    • Pancreatic Cancer
    • TCR-T therapy
    • Guangzhou, Guangdong, China
      Sun Yat-sen Memorial Hospital
    Aug 10, 2022

    Solid Tumors, KRAS Mutation; SOS1 Trial in Germany, Netherlands, United States (BI 1701963, Trametinib)

    Active, not recruiting
    • Solid Tumors, KRAS Mutation; SOS1
    • Boston, Massachusetts
    • +7 more
    Aug 22, 2022

    Colorectal Cancer Trial in Hangzhou (IBI351)

    Not yet recruiting
    • Colorectal Cancer
    • Hangzhou, Zhejiang, China
      The Second Affiliated Hospital of Zhejiang University School of
    Aug 9, 2022

    NSCLC Trial in Philadelphia (Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days))

    Recruiting
    • Non-Small Cell Lung Cancer
    • Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)
    • Philadelphia, Pennsylvania
      Fox Chase Cancer Center
    Jul 29, 2022

    Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression = 1% and an STK11

    Recruiting
    • Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
    • Montpellier, France
    • +7 more
    Dec 19, 2022

    Carcinoma, Non-Small Cell Lung Trial in Netherlands (carboplatin, paclitaxel, Bevacizumab)

    Active, not recruiting
    • Carcinoma, Non-Small Cell Lung
    • Amsterdam, Noord-Holland, Netherlands
    • +27 more
    Dec 6, 2021

    Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic Trial in Chicago (VS-6766, Cetuximab, Pill Diary)

    Not yet recruiting
    • Colorectal Cancer
    • +4 more
    • Chicago, Illinois
      University of Chicago Medical Center
    Jan 6, 2022

    Advanced NSCLC, KRAS Gene Mutation, Lung Cancer Trial in Switzerland (Binimetinib, Pemetrexed, Cisplatin)

    Completed
    • Advanced Non-small Cell Lung Cancer
    • +2 more
    • Basel, Switzerland
    • +3 more
    Jul 13, 2021

    Metastatic Colorectal Cancer, KRAS Gene Mutation Trial (Onvansertib, Bevacizumab, FOLFIRI)

    No longer available
    • Metastatic Colorectal Cancer
    • KRAS Gene Mutation
    • (no location specified)
    Jan 18, 2021

    Pancreatic Ductal Adenocarcinoma Trial in Philadelphia (mDC3/8-KRAS Vaccine)

    Recruiting
    • Pancreatic Ductal Adenocarcinoma
    • mDC3/8-KRAS Vaccine
    • Philadelphia, Pennsylvania
      University of Pennsylvania
    Apr 4, 2022

    NSCLC Trial in Shanghai, Hangzhou (D-1553, Other)

    Not yet recruiting
    • NSCLC
    • Shanghai, Shanghai, China
    • +1 more
    Aug 11, 2022